Print Page  Close Window
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
06/14/17Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference 
06/03/17New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections 
05/24/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017 
05/08/17Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July 
05/04/17Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update 
04/26/17Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017 
04/25/17Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data 
04/24/17Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China 
04/24/17New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections 
04/24/17New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA 
04/18/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017 
04/03/17Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia 
03/27/17Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne 
03/24/17Paratek Pharmaceuticals Opens New Office in King of Prussia 
03/02/17Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 
02/22/17Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 
02/08/17Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference 
01/18/17Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study 
01/04/17Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer